You are here

FDA Approves Duaklir for Treatment of COPD

LAMA/LABA Population Expected to Grow Rapidly in Coming Years

Circassia Pharmaceuticals plc has received FDA approval for Duaklir® for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Duaklir is a fixed-dose combination of the long-acting muscarinic antagonist (LAMA) aclidinium bromide (400 mcg) and long-acting beta-agonist (LABA) formoterol fumarate (12 mcg), administered twice-daily via the Pressair® inhaler. 

The approval is partly based on data from three phase 3 studies, ACLIFORM, AUGMENT, and AMPLIFY. Duaklir’s label includes data from the phase 4 ASCENT study, demonstrating the efficacy of aclidinium therapy in reducing COPD exacerbations. This makes Duaklir the only twice-daily LAMA/LABA in the U.S. with COPD exacerbation data included in its prescribing information.

COPD is the third leading cause of death in the U.S., causing more than 120,000 deaths annually. More than 12 million people have been diagnosed with the condition, but an additional 12 million are estimated to have COPD without knowing it.

Circassia expects to launch Duaklir in the U.S. in the second half of 2019. 

Source: Circassia, April 1, 2019

Recent Headlines

Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
First Anti-PD-1 Therapy Demonstrates Improved Overall Survival
New Test Could Prevent Short- and Long-term Complications
Over 25% of Study Patients Showed 6–12 Months Remission
Researchers Extend Previous Data, Find Association is Reversed